Japan· JP-7223403D1045
テリパラチド酢酸塩
A teriparatide product containing テリパラチド酢酸塩, registered in Japan by 旭化成セラピューティクス, on the national reimbursement list. The same ATC class is registered in 18 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Teriparatide is registered in 18 of 19 countries.
Countries holding a registration under ATC H05AA02 (teriparatide), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 10 of them publish a price we can compare per daily dose
Teriparatide · ATC H05AA02
18 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of teriparatide costs, country by country.
Normalised to the WHO defined daily dose (20 mcg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Teriparatide · price per daily dose (20 mcg)
USD · FX 28 Sept 2026
- CH Switzerland$26.86
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- テリパラチド酢酸塩
- Manufacturer
- 旭化成セラピューティクス
- Country
- Japan (JP)
- ATC code
- H05AA02
- ATC class
- Teriparatide
- Defined daily dose
- 20 mcg, P
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
6 interactions on record for teriparatide.
Graded by severity as the source publishes them — 4 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Teriparatide · interactions on record
6 records
- 4 moderate
- 2 minor
Most severe, free to view
- DigitoxinC01AA04moderate
- DigoxinC01AA05moderate
- CalcipotriolD05AX02moderate
- CalcitriolD05AX03moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under H05AA02
Teriparatide, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/bb774385-d650-4d80-8899-96be08b8b06a GET /v1/drugs/bb774385-d650-4d80-8899-96be08b8b06a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "１００酢酸テリパラチド単位１瓶",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "7223403D1045",
"category": "注射薬",
"price_yen": 18109,
"generic_name": "テリパラチド酢酸塩",
"product_name_jp": null,
"therapeutic_class": "7223",
"transitional_expiry": null
}See everything about teriparatide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.